Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V181 dengue vaccine in healthy children and adolescents
2022-003483-25Phase 3
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dengue fever comparing V181 with Placebo (2 arms). Primary endpoint: Percentage of Participants Experiencing a Medically Attended Adverse Event (MAAE).
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2022-003483-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003483-25.